Abstract Library

#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)

Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C,

Keywords: alkylating agents, pancreatic NET, re-challenge, chemotherapy,

#1828 5-Fluorouracile Plus Dacarbazine in Metastatic Digestive Neuroendoendocrine Tumors: Efficacy and Potential Biomarkers

Introduction: The 5-fluorouracile (5FU) + dacarbazine (DTIC) combination has been poorly evaluated in NET

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: de Mestier L

Authors: De Mestier L, Cros J, Hentic O, Legoux J, Muller N,

Keywords: chemotherapy, tumor response, tolerance, pfs,

#1706 Effectiveness of Chemoterapy in Advanced PanNETs with ki67<55%: Monocentric Experience

Introduction: Pancreatic Neuroendocrine Tumors (panNETs) are neoplasms with heterogeneous clinical behaviour. There is no standard treatment.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Antista M, Cingarlini S, Grego E, Ortolani S, Scarpa A,

Keywords: chemotherapy, neuroendocrine, pan NETs, ki67<55%,

#1537 Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids

Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Bello Roufai D, Planchard D, Walter T, Berdelou A, Guigay J,

Keywords: pulmonary carcinoids, temozolomide, safety,

#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience

Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Grego E

Authors: Grego E, Cingarlini S, Ortolani S, Crosara S, De Robertis R,

Keywords: 3-drugs chemotherapy regimen, pancreatic nets, ki-67% <55%,